You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Study into prophylaxis treatment meets key endpoints

Sanofi and Swedish Orphan Biovitrum AB have announced positive results from the pivotal XTEND-1 phase 3 study into efanesoctocog alfa (BIVV001).